A Radiology Department Just Asked How Your AI Medical Imaging Tool Gets Human Sign-Off Before Clinical Use: Answering the Article 14 Oversight Questions

Your inbox has a new message from the procurement lead at a 500-bed hospital network. Their radiology department wants to deploy your AI-powered imaging analysis tool — but before they can sign, their vendor risk team needs answers to Section 6 of the assessment: "Human Oversight and Clinical Accountability."

The first question: "How does your system ensure that a qualified clinician reviews and validates AI-generated findings before they influence a clinical decision?"

If your tool detects nodules, flags anomalies, or prioritizes worklists, this question is about you. Here's how to answer it — and the follow-up questions that will come next.

Why Medical Imaging AI Triggers Article 14 Questions

EU AI Act Article 14 requires that high-risk AI systems be designed to allow human oversight. For medical imaging AI, the high-risk classification under Annex III is not ambiguous — if your system supports clinical decisions about individuals, you're in scope.

Most radiology AI vendors get tripped up not by the classification question, but by the how do you actually implement oversight question. Saying "a radiologist reviews every finding" is insufficient. Procurement teams want to know how the system makes that review easy, auditable, and non-defeatable.

The 4 Questions You'll Actually Get

1. "How does your system ensure human review before a finding influences a clinical decision?"

What they're asking: Does your product have a hard technical gate — not just a workflow assumption — that prevents clinical action without a qualified reviewer signing off?

How to answer: Be specific about the interaction model. If your tool surfaces a nodule flag in the radiologist's worklist and the radiologist must explicitly accept, modify, or reject each finding before the report is generated, say exactly that. The key phrase: "The system does not generate, transmit, or incorporate a clinical finding into the patient record without explicit clinician confirmation."

If your workflow relies on the radiologist choosing to review (rather than being required to), acknowledge this and explain the safeguards: time-out warnings, queue management rules, or facility-configurable enforcement.

2. "What information does the AI surface to help the clinician validate its output?"

What they're asking: Can a radiologist meaningfully evaluate the AI's finding, or does it produce a score with no interpretable basis?

How to answer: Describe what your explainability layer surfaces at the point of care. Examples of strong answers: saliency maps that highlight the image regions driving the finding, confidence intervals displayed alongside the result, comparison to the distribution of findings in your validation dataset.

Avoid describing your explainability as a research feature or something available only in reports. Procurement teams want to know it's present in the worklist at the moment of review.

3. "Does your system log the radiologist's review decision, and is that log available for audit?"

What they're asking: If a finding is later contested — by the patient, by a regulator, or in litigation — can the hospital prove that a human reviewed and accepted or overrode the AI output?

How to answer: Describe your audit trail. At minimum: each AI finding, the clinician identifier, the action taken (accepted/modified/rejected), the timestamp, and the final output. If the hospital can export this log in a structured format for their own record systems, mention it.

This is where EU AI Act Article 12 (record-keeping) intersects with Article 14. Hospitals asking this question are trying to satisfy their own deployer obligations under Article 26 — they need your logs to close their loop.

4. "What happens if your AI system becomes unavailable mid-shift? Can the radiologist continue working without it?"

What they're asking: Is your AI a dependency that creates operational risk, or a tool that degrades gracefully?

How to answer: Most AI imaging tools operate as a second reader layer — the radiologist can read studies with or without AI output. If that's true for your product, say it clearly: "The AI layer is additive. In the event of unavailability, radiologists continue to read studies using standard workflow. No imaging study is blocked by AI availability."

If your product is more deeply embedded in worklist prioritization, describe the fallback behavior explicitly.

Why These Questions Keep Coming Back

The hospital's vendor risk team is satisfying their own Article 26 deployer obligations. They cannot deploy your tool without evidence that you've built human oversight into the product design — not just into the sales narrative.

The pattern repeats across every enterprise health system procurement you'll encounter. The questions get longer; the underlying concern stays the same: prove that a human is genuinely in the loop.

Try Complizo free at complizo.com